Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metvix Daylight vs Conventional PDT in Mild Actinic Keratosis
NCT01475071Phase 3Completed
- Sponsor
- Galderma
- Start
- Mar 2012
- Primary completion
- Nov 2012
- Modality
- Light/Condition-Responsive Prodrugs
- Countries
- 1
01
Overview
A Phase 3 trial of methyl aminolevulinate in actinic keratosis (AK), sponsored by Galderma. Started Mar 2012; status: completed.
02
Drugs
methyl aminolevulinate
03
Conditions
actinic keratosis (AK)
Beyond the preview
Go deeper on NCT01475071.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01475071.